Sebastian Niezen, Elliot B. Tapper, Hirsh Trivedi, Michelle Lai, Michael P. Curry, Kenneth J. Mukamal, Z. Gordon Jiang – 24 October 2021 – Cirrhosis, a rising cause of death in the United States, has an extended preclinical phase characterized by progressive liver fibrosis. Despite the developments in noninvasive fibrosis measurement, there is no recommended screening, in part due to an incomplete understanding of the disease epidemiology on a national scale. Herein, we aim to define the prevalence of liver fibrosis and compare strategies to identify the at‐risk population.

Qiaofeng Qian, Yang Li, Jiajun Fu, Dewen Leng, Zhe Dong, Jiajun Shi, Hongjie Shi, Dengwei Cao, Xu Cheng, Yufeng Hu, Qiujie Luo, Manli Hu, Yong Ran, Hao Tang, Hui Liu, Jinping Liu – 23 October 2021

Arshi Khanam, Lydia S. Y. Tang, Shyam Kottilil – 23 October 2021

Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda, Masaki Mori – 22 October 2021 – We examined phosphorylated nuclear factor erythroid 2–related factor 2 (P‐NRF2) expression in surgically resected primary hepatocellular carcinoma (HCC) and investigated the association of P‐NRF2 expression with clinicopathological features and patient outcome.

Juan‐Li Duan, Bai Ruan, Ping Song, Zhi‐Qiang Fang, Zhen‐Sheng Yue, Jing‐Jing Liu, Guo‐Rui Dou, Hua Han, Lin Wang – 22 October 2021

Eléanor Luce, Clara Steichen, Mickaël Allouche, Antonietta Messina, Jean‐Marie Heslan, Thierry Lambert, Anne Weber, Tuan Huy Nguyen, Olivier Christophe, Anne Dubart‐Kupperschmitt – 22 October 2021

Marica Meroni, Miriam Longo, Rosa Lombardi, Erika Paolini, Chiara Macchi, Alberto Corsini, Cesare R. Sirtori, Anna Ludovica Fracanzani, Massimiliano Ruscica, Paola Dongiovanni – 21 October 2021 – Dyslipidemia and cardiovascular complications are comorbidities of nonalcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to nonalcoholic steatohepatitis, fibrosis, and cirrhosis up to hepatocellular carcinoma.

Nobuharu Tamaki, Masayuki Kurosaki, Yutaka Yasui, Nami Mori, Keiji Tsuji, Chitomi Hasebe, Kouji Joko, Takehiro Akahane, Koichiro Furuta, Haruhiko Kobashi, Hiroyuki Kimura, Hitoshi Yagisawa, Hiroyuki Marusawa, Masahiko Kondo, Yuji Kojima, Hideo Yoshida, Yasushi Uchida, Toshifumi Tada, Shinichiro Nakamura, Satoshi Yasuda, Hidenori Toyoda, Rohit Loomba, Namiki Izumi – 21 October 2021 – The identification of patients with advanced fibrosis who do not need any further hepatocellular carcinoma (HCC) surveillance after the eradication of hepatitis C is pivotal.

Samuel C. Buchl, Zachary Hanquier, Andrew J. Haak, Yvonne M. Thomason, Robert C. Huebert, Vijay H. Shah, Jessica L. Maiers – 21 October 2021 – Hepatic fibrosis is driven by deposition of matrix proteins following liver injury. Hepatic stellate cells (HSCs) drive fibrogenesis, producing matrix proteins, including procollagen I, which matures into collagen I following secretion. Disrupting intracellular procollagen processing and trafficking causes endoplasmic reticulum stress and stress‐induced HSC apoptosis and thus is an attractive antifibrotic strategy.

Giuseppe Cullaro, Elizabeth C. Verna, Andres Duarte‐Rojo, Matthew R. Kappus, Daniel R. Ganger, Robert S. Rahimi, Brian Boyarsky, Dorry L. Segev, Mara McAdams‐DeMarco, Daniela P. Ladner, Michael L. Volk, Chi‐yuan Hsu, Jennifer C. Lai – 21 October 2021 – Acute kidney injury (AKI) and frailty are major drivers of outcomes among patients with cirrhosis. What is unknown is the impact of physical frailty on the development of AKI. We included adults with cirrhosis without hepatocellular carcinoma listed for liver transplantation at nine US centers (n = 1,033).